“Increased Adoption of Modular, Scalable Bioprocessing Systems”
- A significant and accelerating trend in the global single-use bioreactors for vaccine production market is the growing shift toward modular and scalable bioprocessing solutions, enabling faster setup, flexible production, and reduced contamination risks in both clinical and commercial vaccine manufacturing
- For instance, Sartorius’ BIOSTAT STR single-use bioreactor platform supports rapid deployment and scale-up from bench to production scale, allowing vaccine manufacturers to respond swiftly to outbreaks. Similarly, Thermo Fisher Scientific’s HyPerforma bioreactors are being adopted for their plug-and-play compatibility across upstream processes
- Modular systems integrated with single-use technologies allow manufacturers to tailor vaccine production volumes efficiently, minimize downtime between campaigns, and reduce the need for extensive cleaning and validation, accelerating time-to-market
- In addition, many platforms now support real-time data analytics, automation, and closed-system operations, which enhance process control and compliance with regulatory standards. Companies such as Cytiva and ABEC are investing in flexible manufacturing systems that accommodate a wide range of vaccine modalities including mRNA, viral vector, and protein subunit types
- This trend toward adaptable, ready-to-deploy manufacturing solutions is reshaping how both large biopharma firms and CDMOs approach vaccine production infrastructure. As global demand rises for rapid, scalable solutions, the adoption of advanced single-use bioreactor systems is becoming a cornerstone of modern vaccine manufacturing strategy
- The demand for flexible, high-efficiency bioreactor platforms is growing rapidly across both established and emerging markets, as governments and manufacturers prioritize fast, safe, and cost-effective vaccine production capabilities
